FOR IMMEDIATE RELEASE
June 21, 2011

Drug study for treatment-resistant major depression available in south central Kansas

WICHITA, KAN. – The KU School of Medicine–Wichita is seeking participants for a study that will offer cutting-edge treatment to individuals in Wichita and south central Kansas suffering from treatment-resistant major depression.

The KU School of Medicine–Wichita is one of only 10 sites across the country to conduct this initial study.

“Treatment-resistant major depression is a serious illness from the patients’, their families’, and society’s perspective,” said Sheldon Preskorn, MD, an investigator for the study.

Depression is the leading cause of disability in the United States and is projected to be the leading cause of disability worldwide by 2015-2020 by the World Health Organization.

The KU School of Medicine–Wichita is currently seeking patients who have not benefitted adequately from their current antidepressant treatment. Participants must be between 18 and 65 years old. The study will consist of four visits, including one 24-hour inpatient stay at the KU Wichita Clinical Trial Unit in Wichita. Participants will be compensated for their time.

Those interested in learning more about the study may call (316) 293-1821 or e-mail komo@kumc.edu.

MEDIA NOTE: The number above is for those interested in participating in the study. To schedule an interview or learn more about the study for a story, please contact Cari Merrill at (316) 293-2643 or e-mail cmerrill@kumc.edu.

Naurex, Inc., a clinical-stage private company that develops novel therapies to address unmet needs in psychiatry and neurology, is funding the study.

For more than 35 years, the KU School of Medicine–Wichita has been fulfilling its
mission of “Educating Doctors for Kansas” while improving the health of Kansans by providing hands-on, clinical education in the 3rd and 4th years of medical school. Starting in the fall of 2011, the Wichita campus will expand to a full, four-year program.

###